Literature DB >> 15893894

Impurity formation studies with peptide-loaded polymeric microspheres Part I. In vivo evaluation.

Santos B Murty1, B C Thanoo, Qui Wei, Patrick P DeLuca.   

Abstract

The purpose of the present investigation was to assess the peptide related substances or impurities formed during incubation of drug loaded poly-(D,L-lactide-co-glycolide) (PLGA) and poly-(D,L-lactide) (PLA) microspheres under in vivo conditions. Sprague-Dawley rats were injected with separate batches of octreotide microspheres prepared by either an oil/water or oil/oil dispersion technique. At specified time points (days 14, 22, 30, and 41), animals were sacrificed and microsphere particles were recovered from the subcutaneous injection sites. The recovered particles were further extracted with 1:1 mixture of dimethylsulfoxide:dichloromethane for subsequent impurity analysis by HPLC and mass spectrometry. During incubation, the percentage purity of parent compound depended on the PLGA co-monomer ratio (e.g. 50:50, 85:15, and 100:0 glycolide:lactide ratios). After 41 days of incubation, for instance, octreotide area percentage by HPLC was determined to be approximately 47% for PLGA 50:50 microspheres, approximately 75% for PLGA 85:15 microspheres, and approximately 87% for PLA microspheres. Spectral analysis of particle extracts revealed the presence of peptide related substances with 58 m/z and 72 m/z units higher than the parent peptide m/z value. This indicated the presence of glycoyl and lactoyl covalent substitutions on the drug compound, resulting from chemical interaction between peptide amine groups and PLGA or PLA ester groups.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893894     DOI: 10.1016/j.ijpharm.2005.02.035

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

1.  Reversible blocking of amino groups of octreotide for the inhibition of formation of acylated peptide impurities in poly(lactide-co-glycolide) delivery systems.

Authors:  Jae Hwa Ahn; Eun Ji Park; Hye Suk Lee; Kang Choon Lee; Dong Hee Na
Journal:  AAPS PharmSciTech       Date:  2011-09-21       Impact factor: 3.246

2.  Hollow Microparticles as a Superior Delivery System over Solid Microparticles for the Encapsulation of Peptides.

Authors:  Sharad Kharel; Archana Gautam; Andreas Dickescheid; Say Chye Joachim Loo
Journal:  Pharm Res       Date:  2018-08-02       Impact factor: 4.200

3.  Acylation of exenatide by glycolic acid and its anti-diabetic activities in db/db mice.

Authors:  Rongcai Liang; Xiang Li; Renyu Zhang; Yanan Shi; Aiping Wang; Daquan Chen; Kaoxiang Sun; Wanhui Liu; Youxin Li
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

4.  Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats.

Authors:  Hyun-Hee Kwak; Won-Sik Shim; Seongmee Hwang; Mi-Kyung Son; Yoon-Ji Kim; Tae-Hyoung Kim; Zee-Hye Yoon; Hyun-Jun Youn; Ghun-Il Lee; Soo-Hyoung Kang; Chang-Koo Shim
Journal:  Pharm Res       Date:  2009-09-11       Impact factor: 4.200

5.  Formation of acylated growth hormone-releasing peptide-6 by poly(lactide-co-glycolide) and its biological activity.

Authors:  Dong Hee Na; Jeong Eun Lee; Sun Woo Jang; Kang Choon Lee
Journal:  AAPS PharmSciTech       Date:  2007-06-08       Impact factor: 3.246

6.  The solution and solid state stability and excipient compatibility of parthenolide in feverfew.

Authors:  Ping Jin; Shadi Madieh; Larry L Augsburger
Journal:  AAPS PharmSciTech       Date:  2007-12-14       Impact factor: 3.246

7.  Controlled release of octreotide and assessment of peptide acylation from poly(D,L-lactide-co-hydroxymethyl glycolide) compared to PLGA microspheres.

Authors:  Amir H Ghassemi; Mies J van Steenbergen; Arjan Barendregt; Herre Talsma; Robbert J Kok; Cornelus F van Nostrum; Daan J A Crommelin; Wim E Hennink
Journal:  Pharm Res       Date:  2011-07-09       Impact factor: 4.200

8.  PEGylation of Octreotide Using an α,β-unsaturated-β'-mono-sulfone Functionalized PEG Reagent.

Authors:  Laleh Erfani-Jabarian; Rasoul Dinarvand; Mohammad Reza Rouini; Fatemeh Atyabi; Mohsen Amini; Negar Mohammadhosseini; Abbas Shafiee; Alireza Foroumadi
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.